Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Cancer-derived UTX TPR mutations G137V and D336G impair interaction with MLL3/4 complexes and affect UTX subcellular localization.

Kato H, Asamitsu K, Sun W, Kitajima S, Yoshizawa-Sugata N, Okamoto T, Masai H, Poellinger L.

Oncogene. 2020 Feb 18. doi: 10.1038/s41388-020-1218-3. [Epub ahead of print]

PMID:
32071397
2.

Feed-forward regulatory loop driven by IRF4 and NF-κB in adult T-cell leukemia/lymphoma.

Wong RWJ, Tan TK, Amanda S, Ngoc PCT, Leong WZ, Tan SH, Asamitsu K, Hibi Y, Ueda R, Okamoto T, Ishida T, Iida S, Sanda T.

Blood. 2020 Mar 19;135(12):934-947. doi: 10.1182/blood.2019002639.

PMID:
31972002
3.

HIV Tat/P-TEFb Interaction: A Potential Target for Novel Anti-HIV Therapies.

Asamitsu K, Fujinaga K, Okamoto T.

Molecules. 2018 Apr 17;23(4). pii: E933. doi: 10.3390/molecules23040933. Review.

4.

Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.

Wong RWJ, Ngoc PCT, Leong WZ, Yam AWY, Zhang T, Asamitsu K, Iida S, Okamoto T, Ueda R, Gray NS, Ishida T, Sanda T.

Blood. 2017 Nov 23;130(21):2326-2338. doi: 10.1182/blood-2017-06-792184. Epub 2017 Oct 4.

5.

The Tat/P-TEFb Protein-Protein Interaction Determining Transcriptional Activation of HIV.

Asamitsu K, Okamoto T.

Curr Pharm Des. 2017;23(28):4091-4097. doi: 10.2174/1381612823666170710164148. Review.

PMID:
28699519
6.

MD simulation of the Tat/Cyclin T1/CDK9 complex revealing the hidden catalytic cavity within the CDK9 molecule upon Tat binding.

Asamitsu K, Hirokawa T, Okamoto T.

PLoS One. 2017 Feb 8;12(2):e0171727. doi: 10.1371/journal.pone.0171727. eCollection 2017.

7.

Quantification of the HIV transcriptional activator complex in live cells by image-based protein-protein interaction analysis.

Asamitsu K, Omagari K, Okuda T, Hibi Y, Okamoto T.

Genes Cells. 2016 Jul;21(7):706-16. doi: 10.1111/gtc.12375. Epub 2016 May 19.

8.

Molecular dynamics simulation and experimental verification of the interaction between cyclin T1 and HIV-1 Tat proteins.

Asamitsu K, Hirokawa T, Hibi Y, Okamoto T.

PLoS One. 2015 Mar 17;10(3):e0119451. doi: 10.1371/journal.pone.0119451. eCollection 2015.

9.

A novel IKKα inhibitor, noraristeromycin, blocks the chronic inflammation associated with collagen-induced arthritis in mice.

Ito M, Hamano T, Komatsu T, Asamitsu K, Yamakawa T, Okamoto T.

Mod Rheumatol. 2014 Sep;24(5):775-80. doi: 10.3109/14397595.2013.879416. Epub 2014 Feb 5.

PMID:
24498990
10.

Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly.

Suzuki T, Kasuya Y, Itoh Y, Ota Y, Zhan P, Asamitsu K, Nakagawa H, Okamoto T, Miyata N.

PLoS One. 2013 Jul 16;8(7):e68669. doi: 10.1371/journal.pone.0068669. Print 2013.

11.

Functional characterization of human cyclin T1 N-terminal region for human immunodeficiency virus-1 Tat transcriptional activation.

Asamitsu K, Hibi Y, Imai K, Victoriano AF, Kurimoto E, Kato K, Okamoto T.

J Mol Biol. 2011 Jul 29;410(5):887-95. doi: 10.1016/j.jmb.2011.04.061.

PMID:
21763494
12.

Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression.

Victoriano AF, Imai K, Togami H, Ueno T, Asamitsu K, Suzuki T, Miyata N, Ochiai K, Okamoto T.

FEBS Lett. 2011 Apr 6;585(7):1103-11. doi: 10.1016/j.febslet.2011.03.017. Epub 2011 Mar 12.

13.

A-kinase-interacting protein 1 (AKIP1) acts as a molecular determinant of PKA in NF-kappaB signaling.

Gao N, Hibi Y, Cueno M, Asamitsu K, Okamoto T.

J Biol Chem. 2010 Sep 3;285(36):28097-104. doi: 10.1074/jbc.M110.116566. Epub 2010 Jun 17.

14.

Protecting skin photoaging by NF-kappaB inhibitor.

Tanaka K, Asamitsu K, Uranishi H, Iddamalgoda A, Ito K, Kojima H, Okamoto T.

Curr Drug Metab. 2010 Jun 1;11(5):431-5. Review.

PMID:
20540695
15.

Cyclin T1 stabilizes expression levels of HIV-1 Tat in cells.

Imai K, Asamitsu K, Victoriano AF, Cueno ME, Fujinaga K, Okamoto T.

FEBS J. 2009 Dec;276(23):7124-33. doi: 10.1111/j.1742-4658.2009.07424.x.

16.

Inhibition of inflammatory cytokine production from rheumatoid synovial fibroblasts by a novel IkappaB kinase inhibitor.

Tsuchiya A, Imai K, Asamitsu K, Waguri-Nagaya Y, Otsuka T, Okamoto T.

J Pharmacol Exp Ther. 2010 Apr;333(1):236-43. doi: 10.1124/jpet.109.158899. Epub 2010 Jan 6.

PMID:
20053934
17.

Inhibition of human immunodeficiency virus type 1 replication by blocking IkappaB kinase with noraristeromycin.

Asamitsu K, Yamaguchi T, Nakata K, Hibi Y, Victoriano AF, Imai K, Onozaki K, Kitade Y, Okamoto T.

J Biochem. 2008 Nov;144(5):581-9. doi: 10.1093/jb/mvn104. Epub 2008 Aug 19.

PMID:
18713798
18.

Molecular docking analysis of the protein-protein interaction between RelA-associated inhibitor and tumor suppressor protein p53 and its inhibitory effect on p53 action.

Tomoda K, Takahashi N, Hibi Y, Asamitsu K, Ishida H, Kondo T, Fujii Y, Okamoto T.

Cancer Sci. 2008 Mar;99(3):615-22. doi: 10.1111/j.1349-7006.2007.00723.x. Epub 2008 Jan 15.

19.

AKIP1 enhances NF-kappaB-dependent gene expression by promoting the nuclear retention and phosphorylation of p65.

Gao N, Asamitsu K, Hibi Y, Ueno T, Okamoto T.

J Biol Chem. 2008 Mar 21;283(12):7834-43. doi: 10.1074/jbc.M710285200. Epub 2008 Jan 4.

20.

NF-kappa B signaling and carcinogenesis.

Okamoto T, Sanda T, Asamitsu K.

Curr Pharm Des. 2007;13(5):447-62. Review.

PMID:
17348842

Supplemental Content

Loading ...
Support Center